Abstract
The antimicrobial resistance is an antibiotics inherent problem, which goes hand in hand with their discovery, evolution and clinical use. The quest for new valid targets and the development of new drugs is capital in these days, when the latter antibiotic barrier (vancomycin) has been teared down. Thus, the DNA replication machinery (replisome) gathers lot of characteristics and hopes to be a robust antibacterial target. Five enzymes of the replisome focus the research: (i) topoisomerase type II, (ii) DNA primase, (iii) DNA helicase, (iv) DNA polymerase and (v) DNA ligase. These enzymes, which present characteristics that differentiate the replisome of bacteria from that of virus, archaea or eukaryotes, have been extensively studied in the last decades as antibacterial targets with divergence in outcomes as stated in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aiello D, Barnes MH, Biswas EE et al (2009) Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg Med Chem 17:4466–4476. doi:10.1016/j.bmc.2009.05.014
Ali A, Taylor GE (2005) Development of DNA polymerase IIIC inhibitors for the treatment of gram-positive bacterial infections. Exp Opin Ther Patents 15:947–953. doi:10.1517/13543776.15.8.947
Alt S, Burkard N, Kulik A et al (2011) An artificial pathway to 3,4-dihydroxybenzoic acid allows generation of new aminocoumarin antibiotic recognized by catechol transporters of E. coli. Chem Biol 18:304–313. doi:10.1016/j.chembiol.2010.12.016
Anderle C, Li S, Kammerer B et al (2007) New aminocoumarin antibiotics derived from 4-hydroxycinnamic acid are formed after heterologous expression of a modified clorobiocin biosynthetic gene cluster. J Antibiot (Tokyo) 60:504–510. doi:10.1038/ja.2007.64
Ashiuchi M, Kuwana E, Yamamoto T et al (2002) Glutamate racemase is an endogenous DNA gyrase inhibitor. J Biol Chem 277:39070–39073. doi:10.1074/jbc.C200253200
Bannister T, Nair R, Spicer T et al (2013) ML328: a novel dual inhibitor of bacterial AddAB and RecBCD helicase-nuclease DNA repair enzymes
Bates D (2008) The bacterial replisome: back on track? Mol Microbiol 69:1341–1348. doi:10.1111/j.1365-2958.2008.06378.x
Battistuzzi FU, Feijao A, Hedges SB (2004) A genomic timescale of prokaryote evolution: insights into the origin of methanogenesis, phototrophy, and the colonization of land. BMC Evol Biol 4:44. doi:10.1186/1471-2148-4-44
Beattie TR, Reyes-Lamothe R (2015) A replisome’s journey through the bacterial chromosome. Front Microbiol 6:562. doi:10.3389/fmicb.2015.00562
Berdis AJ (2008) DNA polymerases as therapeutic targets. Biochemistry 47:8253–8260. doi:10.1021/bi801179f
Birch RG, Patil SS (1985) Preliminary characterization of an antibiotic produced by Xanthomonas albilineans which inhibits DNA synthesis in Escherichia coli. J Gen Microbiol 131:1069–1075. doi:10.1099/00221287-131-5-1069
Biswas T, Green KD, Garneau-Tsodikova S, Tsodikov OV (2013a) Discovery of inhibitors of Bacillus anthracis primase DnaG. Biochemistry 52:6905–6910. doi:10.1021/bi4011286
Biswas T, Resto-Roldá NE, Sawyer SK et al (2013b) A novel non-radioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG. Nucleic Acids Res 41:1–13. doi:10.1093/nar/gks1292
Campoli-Richards DM, Monk JP, Price A et al (1988) Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35:373–447
Cheenpracha S, Vidor NB, Yoshida WY et al (2010) Coumabiocins A-F, aminocoumarins from an organic extract of Streptomyces sp. L-4-4. J Nat Prod 73:880–884. doi:10.1021/np900843b
Chu M, Mierzwa R, Xu L et al (2003) Isolation and structure elucidation of Sch 642305, a novel bacterial DNA primase inhibitor produced by Penicillium verrucosum. J Nat Prod 66:1527–1530. doi:10.1021/np0302302
Ciarrocchi G, MacPhee DG, Deady LW, Tilley L (1999) Specific inhibition of the eubacterial DNA ligase by arylamino compounds. Antimicrob Agents Chemother 43:2766–2772
Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92:479–497. doi:10.1007/s00253-011-3557-z
Croom KF, Goa KL (2003) Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769–2802
D’Costa VM, King CE, Kalan L et al (2011) Antibiotic resistance is ancient. Nature 477:457–461. doi:10.1038/nature10388
Davagnino J, Herrero M, Furlong D et al (1986) The DNA replication inhibitor microcin B17 is a forty-three-amino-acid protein containing sixty percent glycine. Proteins 1:230–238. doi:10.1002/prot.340010305
Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417–433. doi:10.1128/MMBR.00016-10
Dwyer DJ, Kohanski MA, Hayete B, Collins JJ (2007) Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 3:91. doi:10.1038/msb4100135
Elshenawy MM, Jergic S, Xu Z-Q et al (2015) Replisome speed determines the efficiency of the Tus-Ter replication termination barrier. Nature 525:394–398. doi:10.1038/nature14866
Emmerson AM, Jones AM (2003) The quinolones: decades of development and use. J Antimicrob Chemother 51(Suppl 1):13–20. doi:10.1093/jac/dkg208
FDA (2013) Fighting the Impact of Antibiotic-Resistant Bacteria
FDA Consumer Health Information (2011) Combating antibiotic resistance
Frick DN, Richardson CC (2001) DNA primases. Annu Rev Biochem 70:39–80. doi:10.1146/annurev.biochem.70.1.39
Gajadeera C, Willby MJ, Green KD et al (2015) Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. J Antibiot (Tokyo) 68:153–157. doi:10.1038/ja.2014.131
Galm U, Dessoy MA, Schmidt J et al (2004) In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach. Chem Biol 11:173–183. doi:10.1016/j.chembiol.2004.01.012
García-Fortanet J, Carda M, Alberto Marco J (2007) Stereoselective synthesis of the bacterial DNA primase inhibitor Sch 642305 and its C-4 epimer. Tetrahedron 63:12131–12137. doi:10.1016/j.tet.2007.09.080
Gatto B, Richter S, Moro S et al (2001) The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage. Nucleic Acids Res 29:4224–4230
Gleckman R, Alvarez S, Joubert DW, Matthews SJ (1979) Drug therapy reviews: oxolinic acid. Am J Hosp Pharm 36:1077–1079
Goldstein EJ (1987) Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity. Am J Med 82:3–17
Greenstein M, Speth JL, Maiese WM (1981) Mechanism of action of cinodine, a glycocinnamoylspermidine antibiotic. Antimicrob Agents Chemother 20:425–432
Griep MA, Blood S, Larson MA et al (2007) Myricetin inhibits Escherichia coli DnaB helicase but not primase. Bioorg Med Chem 15:7203–7208. doi:10.1016/j.bmc.2007.07.057
Guilliam TA, Keen BA, Brissett NC, Doherty AJ (2015) Primase-polymerases are a functionally diverse superfamily of replication and repair enzymes. Nucleic Acids Res 43:6651–6664. doi:10.1093/nar/gkv625
Hale MR, Brassington C, Carcanague D et al (2015) From fragments to leads: novel bacterial NAD+-dependent DNA ligase inhibitors. Tetrahedron Lett 56:3108–3112. doi:10.1016/j.tetlet.2014.12.067
Hastings PJ, Hersh MN, Thornton PC et al (2010) Competition of Escherichia coli DNA polymerases I, II and III with DNA Pol IV in stressed cells. PLoS ONE 5:e10862. doi:10.1371/journal.pone.0010862
Hawkey PM (1998) The origins and molecular basis of antibiotic resistance. BMJ 317:657–660. doi:10.1136/bmj.317.7159.657
Heddle J, Maxwell A (2002) Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 46:1805–1815
Hegde VR, Pu H, Patel M et al (2004) Two new bacterial DNA primase inhibitors from the plant Polygonum cuspidatum. Bioorg Med Chem Lett 14:2275–2277. doi:10.1016/j.bmcl.2004.02.006
Heide L (2009a) The aminocoumarins: biosynthesis and biology. Nat Prod Rep 26:1241–1250. doi:10.1039/b808333a
Heide L (2009b) Aminocoumarins mutasynthesis, chemoenzymatic synthesis, and metabolic engineering. Methods Enzymol 459:437–455. doi:10.1016/S0076-6879(09)04618-7
Heide L (2014) New aminocoumarin antibiotics as gyrase inhibitors. Int J Med Microbiol 304:31–36. doi:10.1016/j.ijmm.2013.08.013
Jaber LA, Bailey EM, Rybak MJ (1989) Enoxacin: a new fluoroquinolone. Clin Pharm 8:97–107
Jiang Y, Pogliano J, Helinski DR, Konieczny I (2002) ParE toxin encoded by the broad-host-range plasmid RK2 is an inhibitor of Escherichia coli gyrase. Mol Microbiol 44:971–979
Johansson E, Dixon N (2013) Replicative DNA polymerases. Cold Spring Harb Perspect Biol 5:a012799–a012799. doi:10.1101/cshperspect.a012799
Jovetic S, Zhu Y, Marcone GL et al (2010) β -Lactam and glycopeptide antibiotics: first and last line of defense? Trends Biotechnol 28:596–604. doi:10.1016/j.tibtech.2010.09.004
Kampranis SC, Maxwell A (1998) The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem 273:22615–22626
Keating GM, Scott LJ (2004) Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 64:2347–2377
Khanam T, Ramachandran R (2014) Exploiting bacterial DNA repair systems as drug targets: a review of the current scenario with focus on mycobacteria. J Indian Inst Sci 94:149–168
King DE, Malone R, Lilley SH (2000) New classification and update on the quinolone antibiotics. Am Fam Physician 61:2741–2748
Kohanski MA, Dwyer DJ, Hayete B et al (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797–810. doi:10.1016/j.cell.2007.06.049
Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol 8:423–435. doi:10.1038/nrmicro2333
Kuron A, Korycka-Machala M, Brzostek A et al (2014) Evaluation of DNA primase DnaG as a potential target for antibiotics. Antimicrob Agents Chemother 58:1699–1706. doi:10.1128/AAC.01721-13
Lahiri SD, Kutschke A, McCormack K, Alm RA (2015) Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 59:5278–5287. doi:10.1128/AAC.00571-15
Landecker H (2015) Antibiotic resistance and the biology of history. Body Soc 1–34. doi:10.1177/1357034X14561341
Lesher GY, Froelich EJ, Gruett MD et al (1962) 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 91:1063–1065
Lewis K (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov 12:371–387. doi:10.1038/nrd3975
Li B, Pai R, Aiello D et al (2013) Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit. Bioorg Med Chem Lett 23:3481–3486. doi:10.1016/j.bmcl.2013.04.055
Livermore DM (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29–i36. doi:10.1093/jac/dkp255
Lowe MN, Lamb HM (2000) Gemifloxacin. Drugs 59:1137–1147 (discussion 1148)
Marceau AH, Bernstein DA, Walsh BW (2013) Protein interactions in genome maintenance as novel antibacterial targets. PLoS One. doi:10.1371/journal.pone.0058765
McHenry CS (2011a) Breaking the rules: bacteria that use several DNA polymerase IIIs. EMBO Rep 12:408–414. doi:10.1038/embor.2011.51
McHenry CS (2011b) DNA replicases from a bacterial perspective. Annu Rev Biochem 80:403–436. doi:10.1146/annurev-biochem-061208-091655
McKay GA, Reddy R, Arhin F et al (2006) Triaminotriazine DNA helicase inhibitors with antibacterial activity. Bioorg Med Chem Lett 16:1286–1290 S0960-894X(05)01501-5 [pii]\r10.1016/j.bmcl.2005.11.076
Mdluli K, Ma Z (2007) Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets 7:159–168. doi:10.2174/187152607781001763
Mehta G, Shinde HM (2005) Enantioselective total synthesis of bioactive natural product (+)-Sch 642305: a structurally novel inhibitor of bacterial DNA primase and HIV-1 tat transactivation. Chem Commun (Camb) 3703–3705. doi:10.1039/b505264e
Meier TI, Yan D, Peery RB et al (2008) Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases. FEBS J 275:5258–5271. doi:10.1111/j.1742-4658.2008.06652.x
Méndez-Alvarez S, Pérez-Hernández X, Claverie-Martín F (2000) Glycopeptide resistance in enterococci. Int Microbiol 3:71–80
Miki T, Chang ZT, Horiuchi T (1984) Control of cell division by sex factor F in Escherichia coli. II. Identification of genes for inhibitor protein and trigger protein on the 42.84-43.6 F segment. J Mol Biol 174:627–646
Mills SD, Eakin AE, Buurman ET et al (2011) Novel bacterial NAD+-dependent DNA ligase inhibitors with broad spectrum activity and antibacterial efficacy in vivo. Antimicrob Agents Chemother 55:1088–1096. doi:10.1128/aac.01181-10
Murphy-Benenato K, Wang H, McGuire HM et al (2014) Identification through structure-based methods of a bacterial NAD(+)-dependent DNA ligase inhibitor that avoids known resistance mutations. Bioorg Med Chem Lett 24:360–366. doi:10.1016/j.bmcl.2013.11.007
Nakanishi A, Oshida T, Matsushita T et al (1998) Identification of DNA gyrase inhibitor (GyrI) in Escherichia coli. J Biol Chem 273:1933–1938
Neville MM, Brown NC (1972) Inhibition of a discrete bacterial DNA polymerase by 6-(p-hydroxyphenylazo)-uracil and 6-(p-hydroxyphenylazo-)-isocytosine. Nat New Biol 240:80–82
Noirot-Gros M-F, Dervyn E, Wu LJ et al (2002) An expanded view of bacterial DNA replication. Proc Natl Acad Sci USA 99:8342–8347. doi:10.1073/pnas.122040799
Oblak M, Kotnik M, Solmajer T (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 14:2033–2047
Oliphant CM, Green GM (2002) Quinolones: a comprehensive review. Am Fam Physician 65:455–464
Perry CM, Ormrod D, Hurst M, Onrust SV (2002) Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 62:169–207
Podos SD, Thanassi JA, Pucci MJ (2012) Mechanistic assessment of DNA ligase as an antibacterial target in Staphylococcus aureus. Antimicrob Agents Chemother 56:4095–4102. doi:10.1128/AAC.00215-12
Robinson A, J Causer R, E Dixon N (2012) Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr Drug Targets 13:352–372. doi:10.2174/138945012799424598
Rock JM, Lang UF, Chase MR et al (2015) DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader. Nat Genet 47:677–681. doi:10.1038/ng.3269
Ruban-Ośmiałowska B, Jakimowicz D, Smulczyk-Krawczyszyn A et al (2006) Replisome localization in vegetative and aerial hyphae of Streptomyces coelicolor. J Bacteriol 188:7311–7316
Samuels DS, Garon CF (1993) Coumermycin A1 inhibits growth and induces relaxation of supercoiled plasmids in Borrelia burgdorferi, the Lyme disease agent. Antimicrob Agents Chemother 37:46–50
Santos-Beneit F, Martín JF, Barreiro C (2014) Glycopeptides and bacterial cell walls. In: Villa TG, Veiga-Crespo P (eds) Antimicrobial compounds. Springer, Berlin, pp 285–311
Sanyal G, Doig P (2012) Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin Drug Discov 7:327–339. doi:10.1517/17460441.2012.660478
Schaeffer P, Headlam M, Dixon N (2004) Protein–protein interactions in the bacterial replisome. Aust Biochem 35:9–12
Schaeffer PM, Headlam MJ, Dixon NE (2005) Protein–protein interactions in the eubacterial replisome. IUBMB Life 57:5–12. doi:10.1080/15216540500058956
Shadrick WR, Ndjomou J, Kolli R et al (2013) Discovering new medicines targeting helicases: challenges and recent progress. J Biomol Screen 18:761–781. doi:10.1177/1087057113482586
Sharma PC, Jain A, Jain S (2009) Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 66:587–604
Shimizu M, Takase Y, Nakamura S et al (1975) Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother 8:132–138
Shrivastava N, Nag JK, Misra-Bhattacharya S (2012) Molecular characterization of NAD+-dependent DNA ligase from Wolbachia endosymbiont of lymphatic filarial parasite Brugia malayi. PLoS ONE 7:e41113. doi:10.1371/journal.pone.0041113
Sissi C, Vazquez E, Chemello A et al (2010) Mapping simocyclinone D8 interaction with DNA gyrase: evidence for a new binding site on GyrB. Antimicrob Agents Chemother 54:213–220. doi:10.1128/AAC.00972-09
Smythe MA, Rybak MJ (1989) Ofloxacin: a review. DICP 23:839–846
Spellberg B, Guidos R, Gilbert D et al (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin Infect Dis 46:155–164. doi:10.1086/524891
Srivastava SK, Dube D, Tewari N et al (2005) Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I. Nucleic Acids Res 33:7090–7101. doi:10.1093/nar/gki1006
Stokes SS, Huynh H, Gowravaram M et al (2011) Discovery of bacterial NAD + -dependent DNA ligase inhibitors: optimization of antibacterial activity. Bioorg Med Chem Lett 21:4556–4560. doi:10.1016/j.bmcl.2011.05.128
Stokes SS, Gowravaram M, Huynh H et al (2012) Discovery of bacterial NAD+-dependent DNA ligase inhibitors: improvements in clearance of adenosine series. Bioorg Med Chem Lett 22:85–89. doi:10.1016/j.bmcl.2011.11.071
Sunchu B, Berg L, Ward HE, Lopper ME (2012) Identification of a small molecule PriA helicase inhibitor. Biochemistry 51:10137–10146. doi:10.1021/bi301100w
Surivet J-P, Lange R, Hubschwerlen C et al (2012) Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity. Bioorg Med Chem Lett 22:6705–6711. doi:10.1016/j.bmcl.2012.08.094
Takei M, Fukuda H, Kishii R, Hosaka M (2001) Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 45:3544–3547. doi:10.1128/AAC.45.12.3544-3547.2001
Tarantino PM, Zhi C, Wright GE, Brown NC (1999) Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria. Antimicrob Agents Chemother 43:1982–1987
Tari LW, Trzoss M, Bensen DC et al (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. Bioorg Med Chem Lett 23:1529–1536. doi:10.1016/j.bmcl.2012.11.032
Teillant A, Laxminarayan R (2015) Economics of antibiotic use in US. Swine and poultry production. Choices 30:1–11
Trzoss M, Bensen DC, Li X et al (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Bioorganic Med Chem Lett 23:1537–1543. doi:10.1016/j.bmcl.2012.11.073
Vickers AA, O’Neill AJ, Chopra I (2007) Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. J Antimicrob Chemother 60:269–273. doi:10.1093/jac/dkm191
Wadworth AN, Goa KL (1991) Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 42:1018–1060
Wang T, Duncan L, Gu W et al (2012) Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-amino-pyrido[2,3-d]pyrimidin-5(8H)-ones. Bioorg Med Chem Lett 22:3699–3703. doi:10.1016/j.bmcl.2012.04.038
Ward VG, Meyer OO (1957) Novobiocin: a review of the literature and a report of experiences with the drug. Wis Med J 56:127–132
Weller GR, Doherty AJ (2001) A family of DNA repair ligases in bacteria? FEBS Lett 505:340–342
WHO (2015) Antimicrobial resistance. WHO, Geneva
WHO (2012) The evolving threat of antimicrobial resistance. Options for action. Options for action, Geneva
Wilkinson A, Day J, Bowater R (2001) Bacterial DNA ligases. Mol Microbiol 40:1241–1248
Wright GD (2007) The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 5:175–186. doi:10.1038/nrmicro1614
Wright GD (2012) Antibiotics: a new hope. Chem Biol 19:3–10. doi:10.1016/j.chembiol.2011.10.019
Wright GE, Brown NC, Xu WC et al (2005) Active site directed inhibitors of replication-specific bacterial DNA polymerases. Bioorg Med Chem Lett 15:729–732 S0960-894X(04)01352-6 [pii]\r10.1016/j.bmcl.2004.11.016
Xu WC, Wright GE, Brown NC et al (2011) 7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity. Bioorg Med Chem Lett 21:4197–4202. doi:10.1016/j.bmcl.2011.05.093
Yang C, Huang C, Li C et al (2002) The terminal proteins of linear Streptomyces chromosomes and plasmids: a novel class of replication priming proteins. Mol Microbiol 43:297–305
Yin Z, Wang Y, Whittell LR et al (2014) DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs. Chem Biol 21:481–487. doi:10.1016/j.chembiol.2014.02.009
Yoshida H, Bogaki M, Nakamura M et al (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647–1650
Acknowledgments
The authors want to thank the European Union program ERA-IB [MySterI (EIB.12.010) project and SCILS project (EIB.12.057)] through the APCIN call of the Spanish Ministry of Economy and Competitiveness (MINECO, Spain) (PCIN-2013-024-C02-01; PCIN-2013-063).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Barreiro, C., Ullán, R.V. (2016). DNA-Synthesizing Enzymes as Antibacterial Targets. In: Villa, T., Vinas, M. (eds) New Weapons to Control Bacterial Growth. Springer, Cham. https://doi.org/10.1007/978-3-319-28368-5_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-28368-5_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28366-1
Online ISBN: 978-3-319-28368-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)